Novo Nordisk Disappoints Investors Amid Plans for Future Blockbuster Drug Launches
Guidance·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.
At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.
Novo NordiskEli LillyMike Doustdar
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.”
Bloomberg — Novo Nordisk Touts Future Blockbuster Launches, Disappointing Investors“<p>At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. </p>”
biopharma dive — Novo talks up drug launches in effort to win back investors“CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.””
fierce biotech — <a href="/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>